benzocaine has been researched along with Ache in 51 studies
Benzocaine: A surface anesthetic that acts by preventing transmission of impulses along NERVE FIBERS and at NERVE ENDINGS.
dextran sulfate sodium : An organic sodium salt of dextran sulfate. It induces colitis in mice.
benzocaine : A benzoate ester having 4-aminobenzoic acid as the acid component and ethanol as the alcohol component. A surface anaesthetic, it is used to suppress the gag reflex, and as a lubricant and topical anaesthetic on the larynx, mouth, nasal cavity, respiratory tract, oesophagus, rectum, urinary tract, and vagina.
Excerpt | Relevance | Reference |
---|---|---|
"A significant pain reduction was observed following the use of ketoprofen when tested against a control gel (placebo)." | 9.22 | The effect of benzocaine and ketoprofen gels on pain during fixed orthodontic appliance treatment: a randomised, double-blind, crossover trial. ( Borzabadi-Farahani, A; Eslamian, L; Gholami, H, 2016) |
"Benzocaine gel caused a decrease in pain perception at 2 h compared with placebo gel." | 9.22 | Effect of 5% benzocaine gel on relieving pain caused by fixed orthodontic appliance activation. A double-blind randomized controlled trial. ( Eslamian, L; Gholami, H; Mortazavi, SA; Soheilifar, S, 2016) |
"This study aims to explore the efficacy of the topical application of 10% benzocaine for treating pruritus and pain as compared to vehicle ointment." | 9.20 | A double-blind, randomized clinical study to determine the efficacy of benzocaine 10% on histamine-induced pruritus and UVB-light induced slight sunburn pain. ( Bauer, M; Lang-Zwosta, I; Nishino, K; Scherzer, T; Schwameis, R; Zeitlinger, M, 2015) |
"In a reference-controlled double-blind trial in patients with acute pharyngitis the effects of a newly developed lozenge containing 8 mg of benzocaine (p-aminobenzoic acid ethyl ester, CAS 94-09-7) were compared with those of an identically dosed commercial pastille." | 9.14 | Double-blind comparison of two types of benzocaine lozenges for the treatment of acute pharyngitis. ( Busch, R; Graubaum, HJ; Grünwald, J; Schmidt, M, 2010) |
"Topical application of EMLA and Oraqix before palatal anesthetic infiltration is associated with less pain than with benzocaine gel." | 9.12 | Comparison of topical anesthetics (EMLA/Oraqix vs. benzocaine) on pain experienced during palatal needle injection. ( Al-Melh, MA; Andersson, L, 2007) |
"5% are significantly more effective than 20% benzocaine in reducing pain from needle stick in the maxillary vestibular mucosa." | 9.11 | Reduction of pain from needle stick in the oral mucosa by topical anesthetics: a comparative study between lidocaine/prilocaine and benzocaine. ( Abu Al-Melh, M; Andersson, L; Behbehani, E, 2005) |
"To compare pain relief in metastatic pancreatic cancer patients between neurolytic celiac plexus block (NCPB) and epidural 5% butamben suspension (EBS), a material-based delivery system of a local anesthetic that produces a long-lasting differential nerve block." | 9.09 | Comparison of epidural butamben to celiac plexus neurolytic block for the treatment of the pain of pancreatic cancer. ( Harris, JE; Ivankovich, AD; Lubenow, TR; Nath, HA; Shulman, M, 2000) |
"Benzocaine did not affect pain scores for any of the two symptoms, nor did it alter global subjective or objective assessment of therapy outcome in treated compared to untreated subjects (P > 0." | 9.08 | Topical benzocaine anaesthesia lacks analgesic effects in painful non-acid oesophagitis. ( Becker, C; Becker, K; Frieling, T; Häussinger, D, 1997) |
"If methemoglobinemia is left untreated, it may be fatal." | 6.44 | Intraoperative detection of methemoglobinemia in a patient given benzocaine spray to relieve discomfort from a nasogastric tube: a case report. ( Young, B, 2008) |
"5 mg benzocaine) provides a rapid analgesic effect and is effective in relieving both severe throat pain as well as difficulty in swallowing associated with acute pharyngitis leading to a 64% improved complete remission within 72 hours." | 5.27 | Efficacy and safety of a triple active sore throat lozenge in the treatment of patients with acute pharyngitis: Results of a multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial (DoriPha). ( Fuchs, K; Milde, J; Palm, J; Schumacher-Stimpfl, A; Stammer, H, 2018) |
"A significant pain reduction was observed following the use of ketoprofen when tested against a control gel (placebo)." | 5.22 | The effect of benzocaine and ketoprofen gels on pain during fixed orthodontic appliance treatment: a randomised, double-blind, crossover trial. ( Borzabadi-Farahani, A; Eslamian, L; Gholami, H, 2016) |
"Benzocaine gel caused a decrease in pain perception at 2 h compared with placebo gel." | 5.22 | Effect of 5% benzocaine gel on relieving pain caused by fixed orthodontic appliance activation. A double-blind randomized controlled trial. ( Eslamian, L; Gholami, H; Mortazavi, SA; Soheilifar, S, 2016) |
"This study aims to explore the efficacy of the topical application of 10% benzocaine for treating pruritus and pain as compared to vehicle ointment." | 5.20 | A double-blind, randomized clinical study to determine the efficacy of benzocaine 10% on histamine-induced pruritus and UVB-light induced slight sunburn pain. ( Bauer, M; Lang-Zwosta, I; Nishino, K; Scherzer, T; Schwameis, R; Zeitlinger, M, 2015) |
"In a reference-controlled double-blind trial in patients with acute pharyngitis the effects of a newly developed lozenge containing 8 mg of benzocaine (p-aminobenzoic acid ethyl ester, CAS 94-09-7) were compared with those of an identically dosed commercial pastille." | 5.14 | Double-blind comparison of two types of benzocaine lozenges for the treatment of acute pharyngitis. ( Busch, R; Graubaum, HJ; Grünwald, J; Schmidt, M, 2010) |
"Topical application of EMLA and Oraqix before palatal anesthetic infiltration is associated with less pain than with benzocaine gel." | 5.12 | Comparison of topical anesthetics (EMLA/Oraqix vs. benzocaine) on pain experienced during palatal needle injection. ( Al-Melh, MA; Andersson, L, 2007) |
"5% are significantly more effective than 20% benzocaine in reducing pain from needle stick in the maxillary vestibular mucosa." | 5.11 | Reduction of pain from needle stick in the oral mucosa by topical anesthetics: a comparative study between lidocaine/prilocaine and benzocaine. ( Abu Al-Melh, M; Andersson, L; Behbehani, E, 2005) |
"Topical benzocaine spray does not appear to offer effective pain control in patients undergoing an endometrial biopsy." | 5.11 | Topical analgesia for endometrial biopsy: a randomized controlled trial. ( Einarsson, JI; Henao, G; Young, AE, 2005) |
"To compare pain relief in metastatic pancreatic cancer patients between neurolytic celiac plexus block (NCPB) and epidural 5% butamben suspension (EBS), a material-based delivery system of a local anesthetic that produces a long-lasting differential nerve block." | 5.09 | Comparison of epidural butamben to celiac plexus neurolytic block for the treatment of the pain of pancreatic cancer. ( Harris, JE; Ivankovich, AD; Lubenow, TR; Nath, HA; Shulman, M, 2000) |
"Pain generated by needle sticks (Ns) for the delivery of local anesthetic and/or scaling and root planing (SRP) instrumentation is commonly addressed by the use of topical anesthetics, such as a benzocaine-gel preparation (BGP)." | 5.09 | Clinical evaluation and comparison of 2 topical anesthetics for pain caused by needle sticks and scaling and root planing. ( Carr, MP; Horton, JE, 2001) |
"The effectiveness of lidocaine and benzocaine in reducing pain produced by needle insertion into the palate was evaluated in a double-blind and placebo-controlled study using a more suitable method." | 5.09 | Clinical effectiveness of lidocaine and benzocaine for topical anesthesia. ( Lavrador, MA; Rosa, AL; Sverzut, CE; Xavier, SP, 1999) |
"To determine the efficacy of Auralgan otic solution (combination product of antipyrine, benzocaine, and glycerin) compared with an olive oil placebo in the management of moderate to severe ear pain in children with acute otitis media (AOM)." | 5.08 | Efficacy of Auralgan for treating ear pain in children with acute otitis media. ( Hoberman, A; Paradise, JL; Reynolds, EA; Urkin, J, 1997) |
"Benzocaine did not affect pain scores for any of the two symptoms, nor did it alter global subjective or objective assessment of therapy outcome in treated compared to untreated subjects (P > 0." | 5.08 | Topical benzocaine anaesthesia lacks analgesic effects in painful non-acid oesophagitis. ( Becker, C; Becker, K; Frieling, T; Häussinger, D, 1997) |
"Benzocaine, in a spray vehicle, confers no benefit when used to decrease pain and anxiety in women undergoing colposcopic procedures." | 5.08 | Ineffectiveness of topical benzocaine spray during colposcopy. ( Andrews, S; Clifton, PA; Shaughnessy, AF, 1998) |
"Butamben (n-butyl-p-aminobenzoic acid) is a pain-relieving local anesthetic for topical use." | 3.78 | Inhibition of sensory neuronal TRPs contributes to anti-nociception by butamben. ( Bang, S; Heo, TH; Hwang, SW; Yang, TJ; Yoo, S, 2012) |
" In another experiment, the preparation was tested in a further 22 subjects for its pain-relieving effect during a standard palatal injection, and compared with 18% benzocaine/2% tetracaine gel." | 3.78 | Relief of palatal injection pain by liposome-encapsulated 2% lignocaine prepared by ultrasonic dental scaler. ( Paphangkorakit, J; Priprem, A; Sangsirinakagul, C, 2012) |
"One hundred twelve emergency patients with irreversible pulpitis received long buccal nerve block injections using 2% lidocaine with 1:100,000 epinephrine." | 3.77 | Long buccal nerve block injection pain in patients with irreversible pulpitis. ( Beck, M; Drum, M; Reader, A, 2011) |
"There was an estimated 75% increased perception of pain on the forearm to which benzoyl peroxide was applied in consort with the topical anesthetic at all examination times." | 3.73 | Decreased efficacy of topical anesthetic creams in presence of benzoyl peroxide. ( Burkhart, CG; Burkhart, CN, 2005) |
" The purpose of this study was to compare the effectiveness of 20% benzocaine in reducing the pain of needle insertion during maxillary posterior and anterior infiltration and inferior alveolar nerve block injections." | 3.72 | Effectiveness of 20% benzocaine as a topical anesthetic for intraoral injections. ( Beck, M; Nusstein, JM, 2003) |
"The cost of treating postepisiotomy pain and edema with foam containing 1% hydrocortisone acetate and 1% pramoxine hydrochloride and a spray with 20% benzocaine was compared in 200 postpartum patients." | 3.67 | Cost analysis of a mucoadhesive foam versus conventional treatment for postepisiotomy patients. ( Bouis, P; Hoffman, M; Johnson, S; Mack, M; Newton, W, 1986) |
" Methemoglobin and oxygen saturation levels did not change compared with baseline after dosing with either treatment." | 2.90 | A Proof-of-concept Study Using Quantitative Sensory Threshold Analysis to Compare Two Intraoral Topical Anesthetics. ( Cooper, SA; Doyle, G; Farrar, JT; Giannakopoulos, H; Hersh, EV; Hutcheson, MC; Lesavoy, B; Mousavian, M; Secreto, S; Wang, P; Wang, S, 2019) |
"If methemoglobinemia is left untreated, it may be fatal." | 2.44 | Intraoperative detection of methemoglobinemia in a patient given benzocaine spray to relieve discomfort from a nasogastric tube: a case report. ( Young, B, 2008) |
"Benzocaine is a commonly used topical anesthetic present in many over-the-counter preparations." | 1.31 | Unexpected cyanosis in the surgical patient. ( Douglass, HO; Lee, JS; Mendez, PA, 2000) |
"Chemotherapy-induced oral mucositis can result in inadequate oral intake, local and systemic infection, a prolonged hospital stay, and increased cost of treatment." | 1.30 | Treating the discomfort of oral ulceration resulting from cancer chemotherapy. ( Haveman, CW; Redding, SW, 1999) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 11 (21.57) | 18.7374 |
1990's | 7 (13.73) | 18.2507 |
2000's | 13 (25.49) | 29.6817 |
2010's | 17 (33.33) | 24.3611 |
2020's | 3 (5.88) | 2.80 |
Authors | Studies |
---|---|
Shekarchi, F | 1 |
Nokhbatolfoghahaei, H | 1 |
Chiniforush, N | 1 |
Mohaghegh, S | 1 |
Haeri Boroojeni, HS | 1 |
Amini, S | 1 |
Biria, M | 1 |
Brignardello-Petersen, R | 1 |
Aziz, M | 1 |
Ahmed, S | 1 |
Qazi, FU | 1 |
Naz, F | 1 |
Shah, M | 1 |
Moorpani, P | 1 |
Palm, J | 1 |
Fuchs, K | 1 |
Stammer, H | 1 |
Schumacher-Stimpfl, A | 1 |
Milde, J | 1 |
Hersh, EV | 1 |
Secreto, S | 1 |
Wang, S | 1 |
Giannakopoulos, H | 1 |
Mousavian, M | 1 |
Lesavoy, B | 1 |
Hutcheson, MC | 1 |
Farrar, JT | 1 |
Wang, P | 1 |
Doyle, G | 1 |
Cooper, SA | 1 |
Vanuytsel, T | 1 |
Karamanolis, G | 1 |
Vos, R | 1 |
Van Oudenhove, L | 1 |
Farré, R | 1 |
Tack, J | 1 |
Gimovsky, A | 1 |
Khodak-Gelman, S | 1 |
Larsen, J | 1 |
Bachman, EA | 1 |
Senapati, S | 1 |
Sammel, MD | 1 |
Kalra, SK | 1 |
Bauer, M | 1 |
Schwameis, R | 1 |
Scherzer, T | 1 |
Lang-Zwosta, I | 1 |
Nishino, K | 1 |
Zeitlinger, M | 1 |
Sandeep, V | 1 |
Kumar, M | 1 |
Jyostna, P | 1 |
Duggi, V | 1 |
Eslamian, L | 2 |
Borzabadi-Farahani, A | 1 |
Gholami, H | 2 |
Mortazavi, SA | 1 |
Soheilifar, S | 1 |
Reznik, DS | 1 |
Jeske, AH | 1 |
Chen, JW | 1 |
English, J | 1 |
Busch, R | 1 |
Graubaum, HJ | 1 |
Grünwald, J | 1 |
Schmidt, M | 1 |
Puglia, C | 1 |
Sarpietro, MG | 1 |
Bonina, F | 1 |
Castelli, F | 1 |
Zammataro, M | 1 |
Chiechio, S | 1 |
Drum, M | 1 |
Reader, A | 1 |
Beck, M | 2 |
de Melo, NF | 1 |
Grillo, R | 1 |
Guilherme, VA | 1 |
de Araujo, DR | 1 |
de Paula, E | 1 |
Rosa, AH | 1 |
Fraceto, LF | 1 |
Bang, S | 1 |
Yang, TJ | 1 |
Yoo, S | 1 |
Heo, TH | 1 |
Hwang, SW | 1 |
Paphangkorakit, J | 1 |
Sangsirinakagul, C | 1 |
Priprem, A | 1 |
Parirokh, M | 1 |
Sadeghi, AS | 1 |
Nakhaee, N | 1 |
Pardakhty, A | 1 |
Abbott, PV | 1 |
Yosefi, MH | 1 |
Deepika, A | 1 |
Rao, CR | 1 |
Vinay, C | 1 |
Uloopi, KS | 1 |
Rao, VV | 1 |
Beekwilder, JP | 1 |
O'Leary, ME | 1 |
van den Broek, LP | 1 |
van Kempen, GT | 1 |
Ypey, DL | 1 |
van den Berg, RJ | 1 |
Raymond, P | 1 |
Johnson, J | 1 |
Primosch, RE | 1 |
BAUMANN, J | 1 |
PICARD-LEROY, G | 1 |
KOHN, J | 1 |
RUTTER, AG | 1 |
VITALI, M | 1 |
GRAHAM, PA | 1 |
Nusstein, JM | 1 |
Einarsson, JI | 1 |
Henao, G | 1 |
Young, AE | 1 |
Abu Al-Melh, M | 1 |
Andersson, L | 2 |
Behbehani, E | 1 |
Burkhart, CG | 1 |
Burkhart, CN | 1 |
Al-Melh, MA | 1 |
Young, B | 1 |
Hoberman, A | 1 |
Paradise, JL | 1 |
Reynolds, EA | 1 |
Urkin, J | 1 |
Becker, K | 1 |
Becker, C | 1 |
Frieling, T | 1 |
Häussinger, D | 1 |
Clifton, PA | 1 |
Shaughnessy, AF | 1 |
Andrews, S | 1 |
Bouis, P | 1 |
Hoffman, M | 1 |
Newton, W | 1 |
Johnson, S | 1 |
Mack, M | 1 |
Shulman, M | 1 |
Harris, JE | 1 |
Lubenow, TR | 1 |
Nath, HA | 1 |
Ivankovich, AD | 1 |
Lee, JS | 1 |
Mendez, PA | 1 |
Douglass, HO | 1 |
Carr, MP | 1 |
Horton, JE | 1 |
Redding, SW | 1 |
Haveman, CW | 1 |
Rosa, AL | 1 |
Sverzut, CE | 1 |
Xavier, SP | 1 |
Lavrador, MA | 1 |
Gill, CJ | 1 |
Orr, DL | 1 |
Vickers, ER | 1 |
Punnia-Moorthy, A | 1 |
Lorino, CO | 1 |
Prough, SG | 1 |
Aksel, S | 1 |
Abuzeid, M | 1 |
Alexander, SE | 1 |
Wiebe, RH | 1 |
Keller, BJ | 1 |
Grasser, H | 1 |
Ackermann, K | 1 |
Weiss, C | 1 |
Pande, YN | 1 |
Gaynor, HM | 1 |
Birke, WP | 1 |
Fürtig, W | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Multi-centre, Randomized, Placebo-controlled, Double-blind, Parallel-group Study Investigating Safety and Efficacy of a Sore Throat Lozenge in the Symptomatic Treatment of Patients With Acute Pharyngitis[NCT03323528] | Phase 4 | 321 participants (Actual) | Interventional | 2017-02-01 | Completed | ||
A Double-blind, Cross-over, Incomplete Factorial Study to Assess the Local Anesthetic Efficacy and Safety of CTY-5339 Anesthetic Spray (CTY-5339A) When Applied to the Gingival Mucosal Tissue in Normal Volunteers[NCT03233737] | Phase 2 | 75 participants (Actual) | Interventional | 2017-06-15 | Completed | ||
A Randomized Controlled Trial of Benzocaine Versus Placebo Spray for Pain Relief at Hysterosalpingogram[NCT01925469] | Phase 4 | 30 participants (Actual) | Interventional | 2011-12-31 | Completed | ||
Effect of Buzzy System (Vibrating Device) Compared to Topical Anaesthesia on Pain Reduction During Injection of Infiltration Anaesthesia in Children: A Randomized Clinical Trial Study.[NCT05083975] | 30 participants (Anticipated) | Interventional | 2022-07-23 | Not yet recruiting | |||
The Effect of Sonophoresis on Topical Anesthesia: a Clinical Trial[NCT01283490] | Phase 1 | 50 participants (Actual) | Interventional | 2011-02-28 | Completed | ||
Efficacy of Ethyl Chloride Topical Anesthesia Application on the Pain Perception During Intra-oral Injections in Children in Comparison to Benzocaine Gel- a Single-blinded Randomized Controlled Trial.[NCT06011005] | 42 participants (Anticipated) | Interventional | 2023-09-01 | Recruiting | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
"The duration of effect, was defined as the time from onset to treatment failure, as measured by QST Heat score. QST Heat scores were the temperature where the sensation of a heat stimuli was felt: ranging from 35 ºC to a maximum of 50.5 ºC with intervals of 0.5 ºC, at a frequency of every 1 minute for the first 5 minutes and then every 5 minutes thereafter until the final 60 minute time point. The QST Heat-based Duration of effect was calculated by the length of time in minutes from onset of anesthesia to the absence of anesthesia where Onset of anesthesia was defined by PPT unless specific QST thresholds were not met. After Onset had been established, absence of analgesia or offset was the first of two time points with consecutive occurrences of regression or absence of analgesia. Reports of QST heat pain temperature by ≥ 3 °C of the Baseline QST indicated analgesia; while a report of similar (<3 °C) than Baseline indicated regression or absence of analgesia. Stage I outcome." (NCT03233737)
Timeframe: Up to one hour post-application
Intervention | minutes (Mean) |
---|---|
Stage I: One Spray CTY-5339-A | 42.5 |
Stage I: One Spray CTY-5339-CB | 6.1 |
Stage I: One Spray CTY-5339-P | 5 |
"The duration of effect, was defined as the length of time in minutes from onset of anesthesia to the absence of anesthesia.Onset was the time point at which the PPT average pain score was less than the Baseline PPT average score by any amount. Also, in 10 minutes or less, the subject must have had a lower PPT average pain score of ≥ 1 unit than Baseline. Absence of anesthesia was defined as follows: After Onset had been established, absence was the first of two time points with consecutive occurrences of regression of absence of analgesia. Reports of less pain by ≥1 unit than Baseline indicated analgesia; while a report of similar (< 1 unit) or more pain than Baseline indicated regression or absence of analgesia. The minimum onset time was 1 minute. PPT scores were assessed using a 0 (no pain) to 10 (severe pain) Numerical Rating Scale at a frequency of every 1 minute for the first 5 minutes and then every 5 minutes thereafter until the final 60 minute time point.~Stage I outcome." (NCT03233737)
Timeframe: Up to one hour post-application
Intervention | minutes (Mean) |
---|---|
Stage I: One Spray CTY-5339-A | 49.2 |
Stage I: One Spray CTY-5339-CB | 21.3 |
Stage I: One Spray CTY-5339-P | 25.2 |
"Response at a time point is defined as having the PPT average pain score of ≤2. PPT scores were assessed using a 0 (no pain) to 10 (severe pain) Numerical Rating Scale at a frequency of every 1 minute for the first 5 minutes and then every 5 minutes thereafter until the final 60 minute time point.~Stage I outcome." (NCT03233737)
Timeframe: Up to one hour post-application
Intervention | minutes (Mean) |
---|---|
Stage I: One Spray CTY-5339-A | 14.5 |
Stage I: One Spray CTY-5339-CB | 2.9 |
Stage I: One Spray CTY-5339-P | 0.2 |
"Onset of anesthesia was defined by Pin Prick Test (PPT) unless specific QST thresholds were not met.~If the PPT Onset was 5 minutes or less, then QST must have been greater than the Baseline QST temperature at 5 minutes by any amount and QST must have been ≥ 3 °C of the Baseline QST at 5 or 10 minutes.~If the PPT Onset was 10 minutes, then QST must have been ≥ 3 °C of the Baseline QST temperature at 10 minutes.~If PPT did not achieve Onset, then QST alone could have achieved onset at either 5 or 10 minutes if QST was greater than the Baseline QST temperature at 5 or 10 minutes by any amount and the QST was ≥ 3 °C of the Baseline QST at 5 or 10 minutes.~QST Heat scores were the temperature where the sensation of a heat stimuli was felt: ranging from 35 ºC to a maximum of 50.5 ºC with intervals of 0.5 ºC, at a frequency of every 1 minute for the first 5 minutes and then every 5 minutes thereafter until the final 60 minute time point.~Stage I outcome." (NCT03233737)
Timeframe: Up to one hour post-application
Intervention | minutes (Mean) |
---|---|
Stage I: One Spray CTY-5339-A | 2.0 |
Stage I: One Spray CTY-5339-CB | 0.4 |
Stage I: One Spray CTY-5339-P | 0.8 |
"Onset of anesthesia was the time point at which the PPT average pain score was less than the Baseline PPT average score by any amount. Also, in 10 minutes or less, the subject must have had a lower PPT average pain score of ≥ 1 unit than the Baseline PPT. Onset was expected to be between 1 and 5 minutes. PPT scores were assessed using a 0 (no pain) to 10 (severe pain) Numerical Rating Scale at a frequency of every 1 minute for the first 5 minutes and then every 5 minutes thereafter until the final 60 minute time point.~Stage I outcome." (NCT03233737)
Timeframe: Up to one hour post-application
Intervention | minutes (Mean) |
---|---|
Stage I: One Spray CTY-5339-A | 1.3 |
Stage I: One Spray CTY-5339-CB | 1.2 |
Stage I: One Spray CTY-5339-P | 2.8 |
"QST Heat scores were the temperature where the sensation of a heat stimuli was felt: ranging from 35 ºC to a maximum of 50.5 ºC with intervals of 0.5 ºC, at a frequency of every 1 minute for the first 5 minutes and then every 5 minutes thereafter until the final 60 minute time point. Reaching maximum heat for QST Heat was defined as subjects reaching the maximum temperature without reporting pain at one or more time points.~Stage I outcome." (NCT03233737)
Timeframe: Any time within one hour post-application
Intervention | Participants (Count of Participants) |
---|---|
Stage I: One Spray CTY-5339-A | 5 |
Stage I: One Spray CTY-5339-CB | 0 |
Stage I: One Spray CTY-5339-P | 0 |
"Response is defined as a subject having a PPT average pain score of ≤2 recorded at any single time point where PPT was performed. PPT scores were assessed using a 0 (no pain) to 10 (severe pain) Numerical Rating Scale at a frequency of every 1 minute for the first 5 minutes and then every 5 minutes thereafter until the final 60 minute time point.~Stage I outcome." (NCT03233737)
Timeframe: Any time within one hour post-application
Intervention | Participants (Count of Participants) |
---|---|
Stage I: One Spray CTY-5339-A | 10 |
Stage I: One Spray CTY-5339-CB | 9 |
Stage I: One Spray CTY-5339-P | 2 |
"The duration of effect, was defined as the time from onset to treatment failure, as measured by QST Heat score. QST Heat scores were the temperature where the sensation of a heat stimuli was felt: ranging from 35 ºC to a maximum of 50.5 ºC with intervals of 0.5 ºC, at a frequency of every 1 minute for the first 5 minutes and then every 5 minutes thereafter until the final 60 minute time point. The QST Heat-based Duration of effect was calculated by the length of time in minutes from onset of anesthesia to the absence of anesthesia where Onset of anesthesia was defined by PPT unless specific QST thresholds were not met. After Onset had been established, absence of analgesia or offset was the first of two time points with consecutive occurrences of regression or absence of analgesia. Reports of QST heat pain temperature by ≥ 3 °C of the Baseline QST indicated analgesia; while a report of similar (<3 °C) than Baseline indicated regression or absence of analgesia. Stage" (NCT03233737)
Timeframe: Up to one hour post-application
Intervention | minutes (Mean) |
---|---|
One Spray CTY-5339-A | 45.5 |
One Spray CTY-5339-CB | 40.8 |
"The duration of effect, was defined as the length of time in minutes from onset of anesthesia to the absence of anesthesia.Onset was the time point at which the PPT average pain score was less than the Baseline PPT average score by any amount. Also, in 10 minutes or less, the subject must have had a lower PPT average pain score of ≥ 1 unit than Baseline. Absence of anesthesia was defined as follows: After Onset had been established, absence was the first of two time points with consecutive occurrences of regression of absence of analgesia. Reports of less pain by ≥1 unit than Baseline indicated analgesia; while a report of similar (< 1 unit) or more pain than Baseline indicated regression or absence of analgesia. The minimum onset time was 1 minute. PPT scores were assessed using a 0 (no pain) to 10 (severe pain) Numerical Rating Scale at a frequency of every 1 minute for the first 5 minutes and then every 5 minutes thereafter until the final 60 minute time point.~Stage II outcome." (NCT03233737)
Timeframe: Up to one hour post-application
Intervention | minutes (Mean) |
---|---|
One Spray CTY-5339-A | 14.6 |
One Spray CTY-5339-CB | 7.4 |
"Response at a time point is defined as having the PPT average pain score of ≤2. PPT scores were assessed using a 0 (no pain) to 10 (severe pain) Numerical Rating Scale at a frequency of every 1 minute for the first 5 minutes and then every 5 minutes thereafter until the final 60 minute time point.~Stage II outcome." (NCT03233737)
Timeframe: Up to one hour post-application
Intervention | minutes (Mean) |
---|---|
One Spray CTY-5339-A | 14.6 |
One Spray CTY-5339-CB | 7.4 |
"Onset of anesthesia was defined by Pin Prick Test (PPT) unless specific QST thresholds were not met.~If the PPT Onset was 5 minutes or less, then QST must have been greater than the Baseline QST temperature at 5 minutes by any amount and QST must have been ≥ 3 °C of the Baseline QST at 5 or 10 minutes.~If the PPT Onset was 10 minutes, then QST must have been ≥ 3 °C of the Baseline QST temperature at 10 minutes.~If PPT did not achieve Onset, then QST alone could have achieved onset at either 5 or 10 minutes if QST was greater than the Baseline QST temperature at 5 or 10 minutes by any amount and the QST was ≥ 3 °C of the Baseline QST at 5 or 10 minutes.~QST Heat scores were the temperature where the sensation of a heat stimuli was felt: ranging from 35 ºC to a maximum of 50.5 ºC with intervals of 0.5 ºC, at a frequency of every 1 minute for the first 5 minutes and then every 5 minutes thereafter until the final 60 minute time point.~Stage II outcome." (NCT03233737)
Timeframe: Up to one hour post-application
Intervention | minutes (Mean) |
---|---|
One Spray CTY-5339-A | 1 |
One Spray CTY-5339-CB | 1.3 |
"Onset of anesthesia was the time point at which the PPT average pain score was less than the Baseline PPT average score by any amount. Also, in 10 minutes or less, the subject must have had a lower PPT average pain score of ≥ 1 unit than the Baseline PPT. Onset was expected to be between 1 and 5 minutes. PPT scores were assessed using a 0 (no pain) to 10 (severe pain) Numerical Rating Scale at a frequency of every 1 minute for the first 5 minutes and then every 5 minutes thereafter until the final 60 minute time point.~Stage II outcome." (NCT03233737)
Timeframe: Up to one hour post-application
Intervention | minutes (Mean) |
---|---|
One Spray CTY-5339-A | 1.1 |
One Spray CTY-5339-CB | 1.1 |
"QST Heat scores were the temperature where the sensation of a heat stimuli was felt: ranging from 35 ºC to a maximum of 50.5 ºC with intervals of 0.5 ºC, at a frequency of every 1 minute for the first 5 minutes and then every 5 minutes thereafter until the final 60 minute time point. Reaching maximum heat for QST Heat was defined as subjects reaching the maximum temperature without reporting pain at one or more time points.~Stage II outcome." (NCT03233737)
Timeframe: Any time within one hour post-application
Intervention | Participants (Count of Participants) |
---|---|
One Spray CTY-5339-A | 7 |
One Spray CTY-5339-CB | 5 |
"Response is defined as a subject having a PPT average pain score of ≤2 recorded at any single time point where PPT was performed. PPT scores were assessed using a 0 (no pain) to 10 (severe pain) Numerical Rating Scale at a frequency of every 1 minute for the first 5 minutes and then every 5 minutes thereafter until the final 60 minute time point.~Stage II outcome." (NCT03233737)
Timeframe: Any time within one hour post-application
Intervention | Participants (Count of Participants) |
---|---|
One Spray CTY-5339-A | 50 |
One Spray CTY-5339-CB | 50 |
"Response at a time point is defined as an increase of QST heat pain temperature by ≥ 3 degrees C compared to the Baseline QST. QST Heat scores were the temperature where the sensation of a heat stimuli was felt: ranging from 35 ºC to a maximum of 50.5 ºC with intervals of 0.5 ºC, at a frequency of every 1 minute for the first 5 minutes and then every 5 minutes thereafter until the final 60 minute time point.~Stage I outcome." (NCT03233737)
Timeframe: Time of application up to one hour post-application
Intervention | Participants (Count of Participants) | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Responded to treatment at the 1 minute time point | Responded to treatment at the 2 minute time point | Responded to treatment at the 3 minute time point | Responded to treatment at the 4 minute time point | Responded to treatment at the 5 minute time point | Responded to treatment at the 10 minute time point | Responded to treatment at the 15 minute time point | Responded to treatment at the 20 minute time point | Responded to treatment at the 25 minute time point | Responded to treatment at the 30 minute time point | Responded to treatment at the 35 minute time point | Responded to treatment at the 40 minute time point | Responded to treatment at the 45 minute time point | Responded to treatment at the 50 minute time point | Responded to treatment at the 55 minute time point | Responded to treatment at the 60 minute time point | |
Stage I: One Spray CTY-5339-A | 7 | 7 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 8 | 6 | 6 | 6 | 6 | 6 | 6 |
Stage I: One Spray CTY-5339-CB | 2 | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
Stage I: One Spray CTY-5339-P | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
"Response at at time point is defined as when the PPT average pain score was less than the Baseline PPT average score by any amount. PPT scores were assessed using a 0 (no pain) to 10 (severe pain) Numerical Rating Scale at a frequency of every 1 minute for the first 5 minutes and then every 5 minutes thereafter until the final 60 minute time point.~Stage I outcome." (NCT03233737)
Timeframe: Time of application up to one hour post-application
Intervention | Participants (Count of Participants) | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Responded to treatment at the 1 minute time point | Responded to treatment at the 2 minute time point | Responded to treatment at the 3 minute time point | Responded to treatment at the 4 minute time point | Responded to treatment at the 5 minute time point | Responded to treatment at the 10 minute time point | Responded to treatment at the 15 minute time point | Responded to treatment at the 20 minute time point | Responded to treatment at the 25 minute time point | Responded to treatment at the 30 minute time point | Responded to treatment at the 35 minute time point | Responded to treatment at the 40 minute time point | Responded to treatment at the 45 minute time point | Responded to treatment at the 50 minute time point | Responded to treatment at the 55 minute time point | Responded to treatment at the 60 minute time point | |
Stage I: One Spray CTY-5339-A | 8 | 9 | 10 | 10 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 8 | 7 | 7 | 6 | 6 |
Stage I: One Spray CTY-5339-CB | 8 | 10 | 10 | 10 | 10 | 10 | 8 | 4 | 4 | 2 | 2 | 1 | 1 | 1 | 1 | 1 |
Stage I: One Spray CTY-5339-P | 4 | 3 | 3 | 3 | 2 | 3 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
"SPID was calculated as a sum of the delta PPT scores at each time point until the designated time point. The delta PPT score is defined as the change in PPT score from baseline. PPT scores were assessed using a 0 (no pain) to 10 (severe pain) Numerical Rating Scale at a frequency of every 1 minute for the first 5 minutes and then every 5 minutes thereafter until the final 60 minute time point.~The total possible scale range was from -100 (best) to +100 (worst) for SPID at the 30 minute time point, and from -160 (best) to +160 (worst) for SPID at the 60 minute time point Lower scores signify a better outcome (less sensitive to pain than at baseline = less pain with therapy = therapy was more effective).~Stage I outcome." (NCT03233737)
Timeframe: Up to one hour post-application
Intervention | score (Mean) | |
---|---|---|
SPID at the 30 minute time point | SPID at the 60 minute time point | |
Stage I: One Spray CTY-5339-A | -82.1 | -128.1 |
Stage I: One Spray CTY-5339-CB | -37.8 | -44.0 |
Stage I: One Spray CTY-5339-P | -29.3 | -53.3 |
"STID was calculated as a sum of the delta QST Heat scores at each time point until the designated time point. The delta QST Heat score is defined as the change in QST Heat score from baseline. QST Heat scores were the temperature where the sensation of a heat stimuli was felt: ranging from 35 ºC to a maximum of 50.5 ºC with intervals of 0.5 ºC, at a frequency of every 1 minute for the first 5 minutes and then every 5 minutes thereafter until the final 60 minute time point.~The total possible scale range was from -155 ºC (best) to +155 ºC (worst) for STID at the 30 minute time point, and from -248 ºC (best) to +248 ºC (worst) for SPID at the 60 minute time point Lower scores signify a better outcome (less sensitive to pain than at baseline = less pain with therapy = therapy was more effective).~Stage I outcome." (NCT03233737)
Timeframe: Up to one hour post-application
Intervention | Degrees Celcius (ºC) (Mean) | |
---|---|---|
STID at the 30 minute time point | STID at the 60 minute time point | |
Stage I: One Spray CTY-5339-A | 153.0 | 320.2 |
Stage I: One Spray CTY-5339-CB | 10.4 | 26.1 |
Stage I: One Spray CTY-5339-P | 72.5 | 134.6 |
"Response at a time point is defined as an increase of QST heat pain temperature by ≥ 3 degrees C compared to the Baseline QST.~QST Heat scores were the temperature where the sensation of a heat stimuli was felt: ranging from 35 ºC to a maximum of 50.5 ºC with intervals of 0.5 ºC, at a frequency of every 1 minute for the first 5 minutes and then every 5 minutes thereafter until the final 60 minute time point.~Stage II outcome." (NCT03233737)
Timeframe: Up to one hour post-application
Intervention | Participants (Count of Participants) | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Responded to treatment at the 1 minute time point | Responded to treatment at the 2 minute time point | Responded to treatment at the 3 minute time point | Responded to treatment at the 4 minute time point | Responded to treatment at the 5 minute time point | Responded to treatment at the 10 minute time point | Responded to treatment at the 15 minute time point | Responded to treatment at the 20 minute time point | Responded to treatment at the 25 minute time point | Responded to treatment at the 30 minute time point | Responded to treatment at the 35 minute time point | Responded to treatment at the 40 minute time point | Responded to treatment at the 45 minute time point | Responded to treatment at the 50 minute time point | Responded to treatment at the 55 minute time point | Responded to treatment at the 60 minute time point | |
One Spray CTY-5339-A | 36 | 37 | 37 | 37 | 37 | 38 | 38 | 36 | 32 | 28 | 24 | 22 | 19 | 17 | 14 | 13 |
One Spray CTY-5339-CB | 29 | 30 | 30 | 30 | 31 | 34 | 31 | 29 | 24 | 19 | 15 | 15 | 12 | 12 | 11 | 9 |
"Response at at time point is defined as when the PPT average pain score was less than the Baseline PPT average score by any amount. PPT scores were assessed using a 0 (no pain) to 10 (severe pain) Numerical Rating Scale at a frequency of every 1 minute for the first 5 minutes and then every 5 minutes thereafter until the final 60 minute time point.~Stage II outcome." (NCT03233737)
Timeframe: Up to one hour post-application
Intervention | Participants (Count of Participants) | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Responded to treatment at the 1 minute time point | Responded to treatment at the 2 minute time point | Responded to treatment at the 3 minute time point | Responded to treatment at the 4 minute time point | Responded to treatment at the 5 minute time point | Responded to treatment at the 10 minute time point | Responded to treatment at the 15 minute time point | Responded to treatment at the 20 minute time point | Responded to treatment at the 25 minute time point | Responded to treatment at the 30 minute time point | Responded to treatment at the 35 minute time point | Responded to treatment at the 40 minute time point | Responded to treatment at the 45 minute time point | Responded to treatment at the 50 minute time point | Responded to treatment at the 55 minute time point | Responded to treatment at the 60 minute time point | |
One Spray CTY-5339-A | 47 | 50 | 50 | 49 | 49 | 49 | 49 | 49 | 48 | 46 | 43 | 36 | 32 | 25 | 20 | 19 |
One Spray CTY-5339-CB | 46 | 48 | 48 | 48 | 49 | 49 | 48 | 46 | 45 | 42 | 34 | 27 | 21 | 20 | 20 | 18 |
"SPID was calculated as a sum of the delta PPT scores at each time point until the designated time point. The delta PPT score is defined as the change in PPT score from baseline. PPT scores were assessed using a 0 (no pain) to 10 (severe pain) Numerical Rating Scale at a frequency of every 1 minute for the first 5 minutes and then every 5 minutes thereafter until the final 60 minute time point.~The total possible scale range was from -100 (best) to +100 (worst) for SPID at the 30 minute time point, and from -160 (best) to +160 (worst) for SPID at the 60 minute time point Lower scores signify a better outcome (less sensitive to pain than at baseline = less pain with therapy = therapy was more effective).~Stage II outcome." (NCT03233737)
Timeframe: Up to one hour post-application
Intervention | score (Mean) | |
---|---|---|
SPID at the 30 minute time point | SPID at the 60 minute time point | |
One Spray CTY-5339-A | -85.2 | -122.6 |
One Spray CTY-5339-CB | -63.2 | -86.6 |
"STID was calculated as a sum of the delta QST Heat scores at each time point until the designated time point. The delta QST Heat score is defined as the change in QST Heat score from baseline. QST Heat scores were the temperature where the sensation of a heat stimuli was felt: ranging from 35 ºC to a maximum of 50.5 ºC with intervals of 0.5 ºC, at a frequency of every 1 minute for the first 5 minutes and then every 5 minutes thereafter until the final 60 minute time point.~The total possible scale range was from -155 ºC (best) to +155 ºC (worst) for STID at the 30 minute time point, and from -248 ºC (best) to +248 ºC (worst) for SPID at the 60 minute time point Lower scores signify a better outcome (less sensitive to pain than at baseline = less pain with therapy = therapy was more effective).~Stage II outcome." (NCT03233737)
Timeframe: Up to one hour post-application
Intervention | Degrees Celcius (ºC) (Mean) | |
---|---|---|
STID at the 30 minute time point | STID at the 60 minute time point | |
One Spray CTY-5339-A | 136.5 | 214 |
One Spray CTY-5339-CB | 96.6 | 149.1 |
The primary outcome is the difference in pain score using a validated visual analog scale before the procedure, which is designated as the pre-procedure (or baseline) pain score to the maximum pain during procedure (designated as time 0) These two pain scores will be subtracted and the change in pain score will be reported. The validated visual analog scale allows patients to report pain on a scale of 0 to 100 mm long. At the beginning and at the end, there are two descriptors representing extremes of pain (i.e. no pain = 0 and extreme pain = 100). The patient rated her pain by making a vertical mark on the 100-mm line. The measurement in millimeters was converted to the same number of points ranging from 0 to 100 points. There are no subgroups. (NCT01925469)
Timeframe: Pre-procedure (Baseline) and procedure (Time 0)
Intervention | mm (Median) |
---|---|
Benzocaine | 50.6 |
Saline Spray | 70.4 |
The patients pain scores will also be assessed at 5 minutes post procedure and the change in pain scores from baseline to this time points will be analyzed. The pain scores will be subtracted to obtain the change in pain score (NCT01925469)
Timeframe: 5 minutes
Intervention | mm (Median) |
---|---|
Benzocaine | -11.1 |
Saline Spray | -37 |
The patient's satisfaction will be assessed using a validated satisfaction scale 30 minutes post procedure. (NCT01925469)
Timeframe: 30 minutes post procedure
Intervention | participants (Number) | ||
---|---|---|---|
Extremely satisfied | Very satisfied | Satisfied | |
Benzocaine | 10 | 2 | 2 |
Saline Spray | 10 | 4 | 0 |
2 reviews available for benzocaine and Ache
Article | Year |
---|---|
Intraoperative detection of methemoglobinemia in a patient given benzocaine spray to relieve discomfort from a nasogastric tube: a case report.
Topics: Accidental Falls; Administration, Oral; Adult; Aerosols; Anesthetics, Local; Benzocaine; Blood Gas A | 2008 |
Does circumcision of the newborn require an anesthetic?
Topics: Anesthetics, Local; Benzocaine; Child Development; Circumcision, Male; Humans; Infant, Newborn; Male | 1968 |
27 trials available for benzocaine and Ache
Article | Year |
---|---|
Evaluating the Preemptive Analgesic Effect of Photo-biomodulation Therapy on Pain Perception During Local Anesthesia Injection in Children: A Split-mouth Triple-blind Randomized Controlled Clinical Trial.
Topics: Analgesics; Anesthesia, Local; Anesthetics, Local; Benzocaine; Child; Gels; Humans; Lidocaine; Mouth | 2022 |
Efficacy and safety of a triple active sore throat lozenge in the treatment of patients with acute pharyngitis: Results of a multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial (DoriPha).
Topics: Acute Disease; Administration, Oral; Adult; Benzalkonium Compounds; Benzocaine; Deglutition; Double- | 2018 |
A Proof-of-concept Study Using Quantitative Sensory Threshold Analysis to Compare Two Intraoral Topical Anesthetics.
Topics: Administration, Topical; Adolescent; Adult; Anesthetics, Local; Benzocaine; Cross-Over Studies; Doub | 2019 |
Role of duodenal mucosal nerve endings in the acid-induced duodenogastric sensorimotor reflex: effect of benzocaine in healthy humans.
Topics: Acids; Adult; Anesthetics, Local; Benzocaine; Cross-Over Studies; Double-Blind Method; Duodenum; Dys | 2013 |
Randomized controlled trial of benzocaine versus placebo spray for pain relief at hysterosalpingogram.
Topics: Adult; Benzocaine; Double-Blind Method; Female; Humans; Hysterosalpingography; Pain; Pain Measuremen | 2014 |
A double-blind, randomized clinical study to determine the efficacy of benzocaine 10% on histamine-induced pruritus and UVB-light induced slight sunburn pain.
Topics: Administration, Topical; Adult; Benzocaine; Double-Blind Method; Histamine; Humans; Male; Ointments; | 2015 |
Evaluation of 2-Stage Injection Technique in Children.
Topics: Administration, Buccal; Adolescent; Anesthesia, Dental; Anesthetics, Local; Benzocaine; Child; Child | 2016 |
The effect of benzocaine and ketoprofen gels on pain during fixed orthodontic appliance treatment: a randomised, double-blind, crossover trial.
Topics: Adolescent; Adult; Anesthetics, Local; Anti-Inflammatory Agents, Non-Steroidal; Benzocaine; Cross-Ov | 2016 |
Effect of 5% benzocaine gel on relieving pain caused by fixed orthodontic appliance activation. A double-blind randomized controlled trial.
Topics: Adolescent; Adult; Analgesics; Benzocaine; Cross-Over Studies; Double-Blind Method; Female; Gels; Gi | 2016 |
Comparative efficacy of 2 topical anesthetics for the placement of orthodontic temporary anchorage devices.
Topics: Adolescent; Adult; Aged; Anesthesia, Dental; Anesthetics, Combined; Anesthetics, Local; Benzocaine; | 2009 |
Double-blind comparison of two types of benzocaine lozenges for the treatment of acute pharyngitis.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Anesthetics, Local; Benzocaine; Chemis | 2010 |
Effect of topical anesthesia on pain during infiltration injection and success of anesthesia for maxillary central incisors.
Topics: Administration, Topical; Adult; Anesthesia, Dental; Anesthesia, Local; Anesthetics, Local; Benzocain | 2012 |
Effectiveness of two flavored topical anesthetic agents in reducing injection pain in children: a comparative study.
Topics: Anesthesia, Dental; Anesthesia, Local; Anesthetics, Combined; Anesthetics, Local; Benzocaine; Child; | 2012 |
Influence of site preparation methods on the pain reported during palatal infiltration using the Wand Local Anesthetic System.
Topics: Administration, Topical; Adult; Anesthesia, Dental; Anesthesia, Local; Anesthetics, Local; Benzocain | 2003 |
Topical analgesia for endometrial biopsy: a randomized controlled trial.
Topics: Administration, Topical; Adult; Aged; Anesthetics, Local; Benzocaine; Biopsy, Needle; Double-Blind M | 2005 |
Reduction of pain from needle stick in the oral mucosa by topical anesthetics: a comparative study between lidocaine/prilocaine and benzocaine.
Topics: Adult; Anesthetics, Combined; Anesthetics, Local; Benzocaine; Cuspid; Humans; Lidocaine; Lidocaine, | 2005 |
Comparison of topical anesthetics (EMLA/Oraqix vs. benzocaine) on pain experienced during palatal needle injection.
Topics: Adult; Anesthesia, Dental; Anesthesia, Local; Anesthetics, Local; Benzocaine; Gels; Humans; Injectio | 2007 |
Efficacy of Auralgan for treating ear pain in children with acute otitis media.
Topics: Acute Disease; Adolescent; Adult; Antipyrine; Benzocaine; Child; Child, Preschool; Double-Blind Meth | 1997 |
Topical benzocaine anaesthesia lacks analgesic effects in painful non-acid oesophagitis.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Analgesia; Anesthetics, Local; Benzocaine; | 1997 |
Ineffectiveness of topical benzocaine spray during colposcopy.
Topics: Administration, Topical; Adult; Anesthetics, Local; Anxiety; Benzocaine; Biopsy; Cervix Uteri; Colpo | 1998 |
Comparison of epidural butamben to celiac plexus neurolytic block for the treatment of the pain of pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Analgesia, Epidural; Anesthetics, Local; Benzocaine; Celiac Plexus; | 2000 |
Clinical evaluation and comparison of 2 topical anesthetics for pain caused by needle sticks and scaling and root planing.
Topics: Administration, Topical; Adult; Aged; Anesthetics, Local; Benzocaine; Bicuspid; Dental Arch; Dental | 2001 |
Clinical effectiveness of lidocaine and benzocaine for topical anesthesia.
Topics: Adolescent; Adult; Analysis of Variance; Anesthesia, Local; Anesthetics, Local; Benzocaine; Double-B | 1999 |
A double-blind crossover comparison of topical anesthetics.
Topics: Administration, Topical; Adult; Anesthetics, Local; Benzocaine; Clinical Trials as Topic; Double-Bli | 1979 |
A clinical evaluation of three topical anaesthetic agents.
Topics: Adult; Anesthetics, Local; Benzocaine; Double-Blind Method; Drug Combinations; Female; Humans; Injec | 1992 |
Comparison of the effectiveness of two topical anesthetics and a placebo in reducing injection pain.
Topics: Administration, Topical; Anesthetics, Local; Benzocaine; Humans; Injections; Pain; Placebos | 1985 |
Double-blind controlled trial of a throat spray containing benzocaine and cetalkonium chloride on postoperative adult tonsillectomy patients.
Topics: Adult; Anti-Infective Agents, Local; Benzocaine; Clinical Trials as Topic; Humans; Pain; Postoperati | 1970 |
22 other studies available for benzocaine and Ache
Article | Year |
---|---|
Topical Cetacaine is probably more effective in preventing pain than benzocaine and an eutectic mixture of local anesthetic before palatal infiltration in children.
Topics: Administration, Topical; Anesthetics, Local; Benzalkonium Compounds; Benzocaine; Cetrimonium Compoun | 2020 |
Effect of pre-cooling agent on intensity of pricking pain at intraoral injection site in adults: An experimental study.
Topics: Adult; Anesthesia, Local; Anesthetics, Local; Benzocaine; Female; Humans; Male; Pain; Pain Measureme | 2021 |
Making chorionic villus sampling painless for both the patient and the physician.
Topics: Administration, Topical; Anesthetics, Local; Benzocaine; Chorionic Villi Sampling; Female; Humans; I | 2014 |
Development, characterization, and in vitro and in vivo evaluation of benzocaine- and lidocaine-loaded nanostructrured lipid carriers.
Topics: Analgesics; Anesthetics, Local; Animals; Benzocaine; Drug Carriers; Humans; Lidocaine; Lipids; Male; | 2011 |
Long buccal nerve block injection pain in patients with irreversible pulpitis.
Topics: Adolescent; Adult; Age Factors; Aged; Anesthetics, Local; Benzocaine; Cheek; Epinephrine; Female; Hu | 2011 |
Poly(lactide-co-glycolide) nanocapsules containing benzocaine: influence of the composition of the oily nucleus on physico-chemical properties and anesthetic activity.
Topics: Anesthetics, Local; Animals; Benzocaine; Cellulose; Chemistry, Pharmaceutical; Drug Carriers; Hydrog | 2011 |
Inhibition of sensory neuronal TRPs contributes to anti-nociception by butamben.
Topics: Anesthetics, Local; Animals; Benzocaine; HEK293 Cells; Humans; Pain; Patch-Clamp Techniques; Sensory | 2012 |
Relief of palatal injection pain by liposome-encapsulated 2% lignocaine prepared by ultrasonic dental scaler.
Topics: Adult; Anesthesia, Dental; Anesthetics, Local; Benzocaine; Female; Humans; Injections; Lidocaine; Li | 2012 |
Kv1.1 channels of dorsal root ganglion neurons are inhibited by n-butyl-p-aminobenzoate, a promising anesthetic for the treatment of chronic pain.
Topics: Action Potentials; Anesthetics, Local; Animals; Benzocaine; Cells, Cultured; Chronic Disease; Gangli | 2003 |
Bye-bye benzocaine?
Topics: 4-Aminobenzoic Acid; Anesthetics, Local; Benzalkonium Compounds; Benzocaine; Cetrimonium Compounds; | 2003 |
[Danger in the use of procaine with butyl aminobenzoate in thoracic surgery].
Topics: Aminobenzoates; Analgesia; Anesthesia; Anesthesia and Analgesia; Benzocaine; Pain; Pain Management; | 1954 |
Prolonged local analgesia with benzocaine-urethane solution.
Topics: Abdomen; Aminobenzoates; Amputation Stumps; Analgesia; Benzocaine; Pain; Pain Management; Urethane | 1954 |
Benzocaine-urethane solution in ophthalmology.
Topics: Aminobenzoates; Analgesia; Anesthesia; Anesthesia and Analgesia; Anesthesia, Conduction; Benzocaine; | 1958 |
Effectiveness of 20% benzocaine as a topical anesthetic for intraoral injections.
Topics: Administration, Topical; Adolescent; Adult; Anesthetics, Local; Benzocaine; Female; Humans; Injectio | 2003 |
Decreased efficacy of topical anesthetic creams in presence of benzoyl peroxide.
Topics: Administration, Topical; Anesthetics, Local; Benzocaine; Benzoyl Peroxide; Drug Interactions; Humans | 2005 |
Cost analysis of a mucoadhesive foam versus conventional treatment for postepisiotomy patients.
Topics: Aerosols; Benzocaine; Cost-Benefit Analysis; Edema; Episiotomy; Female; Humans; Hydrocortisone; Pain | 1986 |
Unexpected cyanosis in the surgical patient.
Topics: Adult; Anesthetics, Local; Benzocaine; Cyanosis; Endoscopy; Female; Humans; Intubation, Gastrointest | 2000 |
Treating the discomfort of oral ulceration resulting from cancer chemotherapy.
Topics: Adult; Anesthetics, Local; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Be | 1999 |
Pain relief in hysterosalpingography. A comparison of analgesics.
Topics: Analgesics; Benzocaine; Dose-Response Relationship, Drug; Drug Combinations; Female; Gels; Humans; H | 1990 |
[Anesthetic and medicated ointments].
Topics: Analgesics; Benzocaine; Gingiva; Gingivitis; Humans; Mouth Mucosa; Ointments; Pain; Stomatitis | 1974 |
Clinical investigation of the use of benzocaine in orabase.
Topics: Anesthesia, Dental; Benzocaine; Dentistry; Methylcellulose; Mouth Diseases; Occlusive Dressings; Oin | 1968 |
[Drug therapy of post extraction pain].
Topics: Adolescent; Adult; Aged; Benzocaine; Child; Dry Socket; Humans; Middle Aged; Ointments; Pain; Postop | 1970 |